Policy reform: Strengthen and stabilize the FDA

Nature

Volumn 485, Issue 7397, 2012, Pages 169-170

  Carpenter, Daniel ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RIMONABANT; SIBUTRAMINE; 1,3-DIMETHYLAMYLAMINE; 4 METHYL 2 HEXYLAMINE; AMINE; MONOCLONAL ANTIBODY;

CONSUMER; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH SERVICE; HERBAL MEDICINE; NOTE; NUTRITION; PRIORITY JOURNAL; PUBLIC HEALTH; SAFETY; ALTERNATIVE MEDICINE; ARTICLE; DRUG TOXICITY; ECONOMICS; GOVERNMENT; HUMAN; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT; STANDARD; TIME; TREATMENT FAILURE; UNITED STATES;

AMINES; ANTIBODIES, MONOCLONAL, HUMANIZED; DIET FADS; DIETARY SUPPLEMENTS; DISCLOSURE; DRUG APPROVAL; DRUG TOXICITY; FEDERAL GOVERNMENT; HUMANS; PUBLIC HEALTH; TIME FACTORS; TREATMENT FAILURE; UNITED STATES; UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84860724291     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/485169a     Document Type: Article

References (7)

1. Carpenter, D. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA (Princeton Univ. Press, 2010).
2. Carpenter, D.US Food and Drug Administration, http://go.nature.com/gtnheq (2011).
3. Roberts, S. A., Allen, J. D. & Sigal, E. V. Health Affairs 30, 1375-1381 (2011).
4. Miller, J. D. J. Am. Med. Assoc. 302, 189-191 (2009).
5. Carpenter, D., Chattopadhyay, J., Moffitt, S. & Nall, C. Am. J. Polit Sci. 56, 89-114 (2012).
6. Cohen, P. A. N. Engl. J. Med. 361, 1523-1525 (2009).
7. Harris, G. White House and the FDA Often at Odds. New York Times (3 April 2012).